Member Info for travel_light

I would have thought 2 degrees and 30 years of experience would have produced a timeline that was a little better than the one produced by a chimp with a dartboard. Well we all live and learn (or not as the case maybe).

There is a book open offering odds at 20:1 that an apology is forthcoming with an acknowledgement that it was all similar to the stuff coming out of bulls rear ends. Think the odds need to be higher to take that bet.

Going to Q and A

Travel light signing off

Pilot batch is a process.

10,000 units

Soon as ready timing will be given

Stressing tech transfer is done right so that clinical validation is smooth

Robust reliable words used

Liverpool design end user testing for consumer

Trying to work in parallel

Others looking at oem deals

Increased affimer production soon ready

Plus external partner

Affimer not bottleneck

Bbi Abington 7’al million tests per month

Need to upscale

Overseas capacity needed

Asia SE Asia ... quality due dillagence

Governments and authorities BUT CONFIDENTIAL

120 m test per month Uk only

Supply multi factor

Saliva tube, pippete

Supply is the worry

Visual test ie no machine. Very confident

Smart phone app to record result

Feed to data systems

Professional
Self cert first

Second consumer takes longer

Hospital market low cos pcr on site, but nurse in
Companies is good market for professional. Also doctors etc

Loosing this writing and listening

Presymptomatic is good????

Graph showing viral
Load verses infectious

High specificy regular testing needed

Sensitivity needed 90% or more

Basically numbers to show where value is

LFD ... do I have infection

Graph about infectioness verses having virus.

Pcr good for early but redial after recovery

7 days for antibody to late

Sweet spot when infected is most infectious

7/10 days after symptoms is where you want to see

Antigen is best

Now doing how BAMs works.

Showing a complicated mass spectrum graph. Finger print. Spot mutation.

Work has been slow trying to accelerate this with condor. Clinical validation Q4. Large commercial interests. Will goto market via mass spectrum seller

Few thousand copies of virus in saliva.

Also very specific. No cross reactivity with common simulate virus

Alister say Elisa test best on market

Dose escalation safety etc 2021

Small number till max dose established.

Range of cancers in study.

Bigger Dose study 1, or 2 cancers in 2022 on back of part A

1,5b per year, 5-10% royalty to Avacta plus dev milestones

How precision works ava6000. Clever stuff

Starts with precision. Filing q4, start late q1, initial data mid 2021

Might be part of back slapping brigade, but my motives are more the product in itself is pretty neat.

My main concern is financing production at volume. 100 dollars a unit 10,000 units to cover say a fair whack of Schools only in uk and that’s a hunk of money. “They will be everywhere” needs a explanation at some point how that happens. But 5 weeks in, it’s innovation etc etc

I don’t look for answers here. More I am hopeful the team can come up with a financing model. China is mentioned, numbers get silly, competition steals tech, risk etc etc like I say either we have faith in team and hold or we don’t and sell, unless we want to trade(how does one get the cojenes for that).

Best of luck all, this is no safe bet but boy is it interesting ;-)

Why not separate positive and negative chips. The Affimers bind the virus.

Could even return negative to user, as no risk of covid, you just checked it.

Then again that buggers business model. Say max 7 days per chip, you know when it was first used. Reuse 7 times then bin it. Or positive, bin it in different bin to burn, recycle the others.

Sitting on the bog, but I am sure team can think this thru.

Burned through millions of share holder money

Explain that to me please.

I disagree about the video. Not massively and you make a good point (before this turns into bun fight just a different opinion).

It left many questions unanswered eg funding of reader production(not too worried).

But having a slick presentation would have made me worried. As a small investor my biggest grumble is lack of information. Often it’s like buying a pig in a poke. Slick is hiding stuff. I thought the team did great, no Oscars, but I kinda went “these guys could make this”. Cooool

Sell it.... that’s another discussion but I think the product will work. I got that from the video.

I had a much better feel where the company is after 5 week project. 5 weeks. Wow proud to be a share holder.

I would have led with derisked stuff more strongly, got everyone waiting. Made the meeting an hour and got the CFO boring everyone with excel(love you really).

Then gone with our “innovation project”. Would I have had a slide after with risks and mitigation yes. Mr B ....the plus’ are lovely to see but we want to make risk choices so need to see both sides when you do thinks like this. You see potential, many are scary cats and need to feel good, be critical of the plan, and work from there.

But a slick video nah, seeing raw bones was way more useful to determine investment case. Big companies do due diligence, video is not much use.

For the actual product and signing up retailers etc, yeah fill you boots, get George Clooney etc

The SP got heated, many head 2+2 and made 1M.

Omelette, eggs, etc

Fast bucks yeah be nice wish I’d sold and bought back in:-). But so long as we don’t dilute like hell to gamble I’m fine. If we need cash let those of us holding shares have first go (Avacta....). Then goto II.

Anyway, I agree perception is important, but risk slides rather than George C would be better.